Clear Street raised the firm’s price target on Enliven (ELVN) to $55 from $36 and keeps a Buy rating on the shares. The firm left meetings with management with increased conviction in ELVN-001 as a differentiated ATP-site binder for BCR-ABL1.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven Therapeutics: Strengthening ELVN-001 Profile and M&A Optionality Support Buy Rating and $56 Price Target
- Leveraging Merck–Terns Benchmark: Supporting Enliven’s ELVN-001 Upside and a Raised $60 Buy Target
- Enliven rises 11.0%
- Enliven price target raised to $56 from $48 at H.C. Wainwright
- Clear Street says Merck’s bet on TERN-701 sharpens investment case for ELVN-001